The FDA has issued warning letters to multiple companies marketing compounded Retatrutide, an investigational drug from Eli Lilly still in Phase II trials. While early studies have shown promising weight loss results, Retatrutide FDA's Overreach on Compounded Peptides Regeneration or Risk? A Narrative Review of BPC 157 for Musculoskeletal Healing Current Reviews in Musculoskeletal Medicine Springer Nature Link FDA warning letters target marketers of unapproved weight loss drugs RAPS BPC 157 Weight Loss: Evidence & Safety